Relatlimab and Nivolumab for Young Lymphoma Patients

We are studying a combination of two medications for children and young adults with recurrent or hard-to-treat Hodgkin and Non-Hodgkin lymphoma. The goal is to understand their safety and how well they may work.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Opdivo
Opdivo is a cancer medicine that helps the immune system find and fight tumor cells.
Relatrom

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Eltrombopag
Eltrombopag is a substance that increases platelet production to help manage low platelet counts.
Nivolumab
Nivolumab is a substance that helps the immune system recognize and attack certain cancers.
Relatlimab
Relatlimab is an antibody that blocks the LAG-3 immune checkpoint to help the immune system attack certain cancers.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Elrevolan
Eltrombgopa Glenmark
Eltrombopag

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Regional D'Angers
Pediatric immuno-hemato-oncology
Angers, France
Centre Hospitalier Universitaire De Bordeaux
Pediatric hematology and oncology
Bordeaux, France
Centre Hospitalier Universitaire De Caen Normandie
Pediatric hematology and oncology
Caen, France

Sponsor: Bristol Myers Squibb International Corporation
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.